Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory securities lawsuit

Capricor Securities Class Action Deadline

Analysis based on 6 articles · First reported Sep 21, 2026 · Last updated Sep 23, 2026

Sentiment
-10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The lawsuit introduces legal and regulatory uncertainty for Paragon Therapeutics, potentially pressuring its stock price and increasing volatility as investors assess the risk of adverse outcomes. The broader biotechnology sector may see minor negative sentiment as the case highlights regulatory and disclosure risks in drug development.

biotechnology pharmaceuticals legal services

Rosen Law Firm has filed a securities class action lawsuit against Paragon Therapeutics, Inc. on behalf of investors who purchased Capricor securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor made materially false and misleading statements and failed to disclose that it adopted changes to the pre-specified statistical analysis plan for its cell therapy Deramiocel without prior FDA agreement, creating a significant risk that the FDA would find the clinical results insufficient for effectiveness and jeopardizing regulatory approval for Duchenne muscular dystrophy treatment. The firm has issued reminders to investors about the September 28, 2026 lead plaintiff deadline. Investors may join the class action without out-of-pocket fees through a contingency fee arrangement. The case is pending in court, and no class has been certified yet. The lawsuit claims investors suffered damages when the true details entered the market.

90 Rosen Law Firm filed class action Paragon Therapeutics
30 Rosen Law Firm reminded investors
priv
Capricor is the defendant in the securities class action, facing allegations of misleading investors regarding its Deramiocel BLA and statistical analysis plan changes. The lawsuit and upcoming lead plaintiff deadline could negatively affect its stock price and reputation.
Importance 100.0 Sentiment -40.0
priv
Rosen Law Firm is the plaintiff's counsel that filed the class action and is reminding investors of the deadline. The firm's involvement is central to the litigation, but its market sentiment is largely neutral as it represents investor interests.
Importance 80.0 Sentiment 10.0
govactor
The FDA is mentioned as the regulatory body that had not agreed to Capricor's statistical analysis plan changes, which is central to the allegations. The agency's actions or lack thereof are key to the lawsuit's claims.
Importance 60.0 Sentiment 0.0
per
Philip Kim is an attorney at Rosen Law Firm listed as a contact for the class action. His role is procedural and does not directly affect market sentiment.
Importance 20.0 Sentiment 0.0
per
Lawrence Rosen is a founding partner of Rosen Law Firm and a contact for the class action. His involvement is peripheral to the market impact of the event.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.